Home

JONATHAN SILVERSTEIN

CIK 1171005 · last filed 2020-10-06

JONATHAN SILVERSTEIN is a corporate insider who has filed 49 SEC Form 4 insider transactions across 12 companies since 2007. The most recent filing shows the insider bought $12.4M of ARQT on Oct 6, 2020. Across all open-market trades the lifetime net is −$235.9M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $359.3M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$359.35M

Companies

12

Total Filings

49

Lifetime Open-Market Net

-$235.88M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
ARQT Director 4,267,564 $25.92 $110.62M $21.90M 3 2020-10-06
Adicet Bio, Inc. (TORC) Delisted Director 613,865 — — $8.00M 3 2020-06-05
AVEDRO INC (AVDR) Delisted Director 0 $24.25 $0 $0 3 2019-11-25
GKOS Director 66,790 $181.42 $12.12M -$104.42M 11 2018-03-06
scPharmaceuticals Inc. (SCPH) Delisted Director 2,576,532 $5.67 $14.61M $0 1 2017-11-21
Roka BioScience, Inc. (ROKA) Delisted Director 227,307 — — $4.60M 4 2016-09-23
BOLD Director 4,435,538 $2.82 $12.51M $500.0K 2 2016-08-25
INTERCEPT PHARMACEUTICALS, INC. (ICPT) Delisted Director 1,121,583 $19.00 $21.31M -$174.29M 16 2015-11-27
Relypsa Inc (RLYP) Delisted Director 3,810,642 — — $7.83M 1 2013-11-20
NxStage Medical, Inc. (NXTM) Delisted Director — — — $0 3 2010-05-28
PODD Director 1,568,841 $142.85 $224.11M $0 1 2007-05-18
AVANIR PHARMACEUTICALS, INC. (AVNR) Delisted Director 2,374,190 — — $0 1 2007-03-05

Recent Filings

49 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2020-10-06 ARQT Buy (P) +496,000 $12.40M EDGAR
2020-06-05 Adicet Bio, Inc. (TORC) Delisted Grant (A) — $0 EDGAR
2020-03-03 ARQT Grant (A) — $0 EDGAR
2020-02-04 ARQT Mixed +4,673,850 $9.50M EDGAR
2019-11-25 AVEDRO INC (AVDR) Delisted Disp (D) −4,240,128 $0 EDGAR
2019-06-18 AVEDRO INC (AVDR) Delisted Grant (A) — $0 EDGAR
2019-05-09 Adicet Bio, Inc. (TORC) Delisted Grant (A) — $0 EDGAR
2019-02-19 AVEDRO INC (AVDR) Delisted Mixed +4,087,710 $0 EDGAR
2018-03-06 GKOS Sell (S) −836,500 -$26.79M EDGAR
2018-01-30 Adicet Bio, Inc. (TORC) Delisted Mixed +4,830,387 $8.00M EDGAR
Showing 1–10 of 49
Page 1 of 5
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.